MAPT and early-onset autosomal dominant Alzheimer disease: At the time of injection, these mice had no discernible endogenous tau pathology, which allowed us to evaluate the effectiveness of the antibodies at reducing pathology induced by the injection of human Alzheimer’s disease lysates.